Table 2.
Change in prevalence of GDM using the IADPSG criteria
| Country | Baseline prevalence | IADPSG | Absolute change from local reference criteria | Fold change from local criteria | ||
|---|---|---|---|---|---|---|
| ADAa | WHOb 1999 | Regional | ||||
| Norway [29] | 13% | 31.5%a | +18.5% | 2.42 | ||
| UAE [1•] | 12% | 24.5% | 45.3% | +33.3% | 3.78 | |
| Nigeria [30] | 3.8% | 8.6% | +4.8% | 2.26 | ||
| New Zealand [31] | 6%c | 10% | +4% | 1.67 | ||
| Norway [32] | 6.1% | 7.4%a | +1.3% | 1.21 | ||
| Brazil [47] | 7.1% | 18% | +10.9% | 2.53 | ||
| Spain [33••] | 10.6% | 35.5% | +24.9% | 3.35 | ||
| Ireland [34] | 9.4% | 12.4% | +3% | 1.32 | ||
| Japan [35] | 2.4%d | 6.6% | +4.2% | 2.75 | ||
| Vietnam [36] | 6.1% | 20% | +13.9% | 3.28 | ||
| Mediterranean [37] | 8.7% | 26.6% | +17.9% | 3.06 | ||
| Turkey [38] | 6% | 14.5% | +8.5% | 2.42 | ||
| Nepal [39] | 2.5% | 6.6% | +4.1% | 2.64 | ||
| China [40] | 8.4% | 18.9% | +10.5% | 2.25 | ||
| Saudi Arabia [41] | 16.9%e | 41.5% | +24.6% | 2.46 | ||
| Western Australia [42] | 3.4%f | 3.5% | +0.1% | 1.03 | ||
| Canada [43] | 7.3%g | 10.2% | +2.9% | 1.40 | ||
| India [44] | 13.4% | 14.6% | +1.2% | 1.09 | ||
| Hungary [45] | 8.7% | 16.6% | +7.9% | 1.91 | ||
| Mexico [46] | 10.3% | 30.1% | +19.8% | 2.92 | ||
| Bulgaria [18] | 13.5% | 17.1% | 31.6% | +18.1% | 1.85 | |
aTwo-step 100-g OGTT using either CC or NDDG criteria
bWorld Health Organization (WHO)
cUsing New Zealand Society for the Study of Diabetes (NZSDD) criteria
dUsing Japan Society for Obstetrics and Gynecology (JSOG) criteria
eTwo-step ADA criteria but a 75-g OGTT
fUsing Australasian Diabetes in Pregnancy Society (ADIPS) criteria
gUsing Canadian Diabetes Association (CDA) 2008